Eupatilin

The marquee. As an isolate, eupatilin reduced ethanol-induced gastric mucosal lesions and oxidative/inflammatory markers in rats ^{1Reference 1Jang DR et al. · 2024Gastroprotective effect of eupatilin, a polymethoxyflavone from Artemisia argyi, in ethanol-induced gastric injuryView study →} and blunted oxidative damage in gastric epithelium (with heme-oxygenase-1 induction rather than acid suppression) ^{2,3Reference 2Choi EJ et al. · 2008Eupatilin protects gastric epithelial cells from oxidative damage and downregulates genes responsible for oxidative stressView study →Reference 3Choi EJ et al. · 2009Eupatilin, with heme-oxygenase-1-inducing ability, protects cultured feline esophageal epithelial cells from cell damageView study →}. The extract DA-9601 (Stillen; reformulated DA-5204/Stillen 2X) — for which eupatilin is the marker — has real Phase III human trials in erosive gastritis ^{4Reference 4Choi HS et al. · 2004RCTDA-9601 for erosive gastritis: a double-blind placebo-controlled phase III clinical trialView study →} and randomised trials preventing NSAID-associated gastroduodenal injury ^{5Reference 52011RCTPrevention of NSAID-associated gastroduodenal injury in healthy volunteers — a randomised, double-blind, multicentre study (DA-9601)View study →}, comparable to misoprostol ^{6Reference 62014A comparative study of DA-9601 and misoprostol for prevention of NSAID-associated gastroduodenal injuryView study →}, to its new formulation ^{7Reference 72017Clinical trialEfficacy and safety of DA-9601 versus its new formulation DA-5204 in patients with gastritisView study →} and to PPI/rebamipide ^{8Reference 82024DA-9601 has protective effects comparable to those of a proton-pump inhibitor and rebamipide against NSAID-related gastropathyView study →}.

Gap: every human trial dosed the whole standardised extract, never purified eupatilin — the isolate’s own gastroprotection is entirely rat/cell-level, so clinical credit belongs to DA-9601, not eupatilin ^{4,6Reference 4Choi HS et al. · 2004RCTDA-9601 for erosive gastritis: a double-blind placebo-controlled phase III clinical trialView study →Reference 62014A comparative study of DA-9601 and misoprostol for prevention of NSAID-associated gastroduodenal injuryView study →}.

Eupatilin suppressed allergic inflammatory mediators in vitro and in vivo ^{9Reference 92018In vitroEupatilin suppresses the allergic inflammatory response in vitro and in vivoView study →}, improved atopic-dermatitis-like skin lesions applied topically in mice ^{10Reference 102017AnimalTopical application of eupatilin ameliorates atopic-dermatitis-like skin lesions in NC/Nga miceView study →}, and reduced disease severity in collagen-induced arthritis ^{11Reference 112015Eupatilin ameliorates collagen-induced arthritisView study →}, with NF-κB/MAPK suppression the recurring mechanism.

Gap: small rodent/cell models with no human isolate trials, and some readouts overlap the extract’s gastritis mechanism rather than being independently replicated ^{9,11Reference 92018In vitroEupatilin suppresses the allergic inflammatory response in vitro and in vivoView study →Reference 112015Eupatilin ameliorates collagen-induced arthritisView study →}.

Eupatilin induced apoptosis in human gastric cancer cells ^{12Reference 12Kim DH et al. · 2005Eupatilin, a pharmacologically active flavone from Artemisia, induces apoptosis in human gastric cancer cellsView study →}, produced cell-cycle arrest with a differentiation phenotype ^{13Reference 132009Eupatilin exhibits a novel anti-tumour activity through the induction of cell-cycle arrest and differentiationView study →}, and drove ROS-mediated MAPK and PI3K/AKT apoptosis in renal cancer cells ^{14Reference 142016Eupatilin induces human renal cancer cell apoptosis via ROS-mediated MAPK and PI3K/AKT signallingView study →}.

Gap: overwhelmingly in-vitro at µM concentrations, scattered across single labs, with minimal in-vivo tumour work and no human data — hypothesis-generating, not clinical ^{12,14Reference 12Kim DH et al. · 2005Eupatilin, a pharmacologically active flavone from Artemisia, induces apoptosis in human gastric cancer cellsView study →Reference 142016Eupatilin induces human renal cancer cell apoptosis via ROS-mediated MAPK and PI3K/AKT signallingView study →}.

Eupatilin inhibits H₂O₂-induced apoptosis through MAPK modulation ^{15Reference 152008Eupatilin inhibits H₂O₂-induced apoptotic cell death through inhibition of mitogen-activated protein kinasesView study →}, and the HO-1/anti-oxidative mucosal mechanism underlies its gastric-epithelial cytoprotection ^{3Reference 3Choi EJ et al. · 2009Eupatilin, with heme-oxygenase-1-inducing ability, protects cultured feline esophageal epithelial cells from cell damageView study →}.

Gap: in-vitro and hard to separate from the gastroprotective dataset — a methoxyflavone class-level antioxidant property, not a standalone clinical claim ^{3,15Reference 3Choi EJ et al. · 2009Eupatilin, with heme-oxygenase-1-inducing ability, protects cultured feline esophageal epithelial cells from cell damageView study →Reference 152008Eupatilin inhibits H₂O₂-induced apoptotic cell death through inhibition of mitogen-activated protein kinasesView study →}.